144510.KQ
GC Cell Corporation
KOE · Healthcare · Biotechnology · KR
KRW 14,760.00
+7.74%Year over year
Reported trailing growth
- Revenue
- -5.0%
- EBITDA
- +83.0%
- EBIT
- +48.6%
- EPS
- —
- Free cash flow
- +187.0%
- Operating cash flow
- +370.6%
Forward estimates
Based on analyst estimates
- Revenue
- -43.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -11.2%
- EBITDA
- -68.3%
- EBIT
- +31.0%
- Net income
- —
- EPS
- —
- Free cash flow
- -58.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026